Unlike the ADCs used for HER2-positive BC treatment, which involve anti-HER2 antibodies, sacituzumab govitecan (IMMU-132) is composed of an anti-human trophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody, allowing it to target triple-negative breast cancer cells. Here, TACSTD2 is linked to triple-negative breast carcinoma.